Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study Of Diflucan In Children With Ringworm Of The Scalp
This study has been completed.
Study NCT00645242   Information provided by Pfizer
First Received: March 25, 2008   No Changes Posted

March 25, 2008
March 25, 2008
November 2002
 
Combined clinical and mycological outcome at Week 6 [ Time Frame: Week 6 ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
  • Clinical outcome based on signs and symptoms at Weeks 3, 6, and 10 [ Time Frame: Weeks 3, 6, and 10 ] [ Designated as safety issue: No ]
  • Combined clinical and mycological outcome at Weeks 3 and 10 [ Time Frame: Weeks 3 and 10 ]
  • Mycological outcome based on culture results at Weeks 3, 6, and 10 [ Time Frame: Weeks 3, 6, and 10 ] [ Designated as safety issue: No ]
  • Culture results at Weeks 3, 6, and 10 [ Time Frame: Weeks 3, 6, and 10 ]
Same as current
 
A Study Of Diflucan In Children With Ringworm Of The Scalp
An Open Label, Multicenter Trial Of Diflucan (Fluconazole) For 6 Weeks Given Once Daily To Pediatric Patients With Tinea Capitis

The purpose of this study is to evaluate the safety and efficacy of fluconazole for the treatment of tinea capitis in pediatric patients aged 3 to 12 years.

 
Phase III
Interventional
Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study
Tinea Capitis
Drug: fluconazole
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
185
March 2003
 

Inclusion Criteria:

  • Pediatric patients (aged 3-12 years)
  • Clinical diagnosis of tinea capitis
  • Direct microscopy (KOH) positive for fungal elements within or outside hair shaft

Exclusion Criteria:

  • Negative baseline KOH
  • Liver disease
Both
3 Years to 12 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Puerto Rico
 
NCT00645242
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
A0561017
Pfizer
 
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
March 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP